Lifesci Capital Has Strong Estimate for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Lifesci Capital boosted their FY2025 earnings estimates for shares of Soleno Therapeutics in a report released on Wednesday, November 5th. Lifesci Capital analyst K. Dellorusso now expects that the company will earn ($0.24) per share for the year, up from their prior estimate of ($0.87). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q4 2025 earnings at $0.46 EPS, Q1 2026 earnings at $0.56 EPS, Q2 2026 earnings at $0.69 EPS and FY2026 earnings at $3.32 EPS.

A number of other equities analysts have also recently commented on SLNO. Guggenheim reaffirmed a “buy” rating and issued a $106.00 price target on shares of Soleno Therapeutics in a research note on Wednesday, August 27th. Oppenheimer lifted their target price on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and issued a $110.00 price target (up previously from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Finally, Robert W. Baird set a $121.00 price objective on shares of Soleno Therapeutics and gave the company an “outperform” rating in a research report on Friday, July 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Soleno Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $114.50.

Soleno Therapeutics Trading Up 9.6%

NASDAQ SLNO opened at $47.70 on Friday. The firm has a market cap of $2.54 billion, a PE ratio of -11.52 and a beta of -2.92. Soleno Therapeutics has a 1-year low of $41.50 and a 1-year high of $90.32. The stock has a 50-day moving average of $62.30 and a 200-day moving average of $72.92. The company has a current ratio of 15.13, a quick ratio of 15.01 and a debt-to-equity ratio of 0.21.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.39. The business had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in shares of Soleno Therapeutics in the second quarter worth $25,000. Nisa Investment Advisors LLC boosted its stake in Soleno Therapeutics by 287.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after purchasing an additional 400 shares in the last quarter. AlphaQuest LLC boosted its stake in Soleno Therapeutics by 37.5% in the 1st quarter. AlphaQuest LLC now owns 983 shares of the company’s stock worth $70,000 after purchasing an additional 268 shares in the last quarter. Osaic Holdings Inc. grew its position in Soleno Therapeutics by 97.7% during the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after purchasing an additional 423 shares during the last quarter. Finally, KBC Group NV bought a new stake in Soleno Therapeutics during the 2nd quarter valued at about $77,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.